BENGALURU: AI healthcare company Reveal HealthTech has secured $7.2 million in a Series A funding round led by Leo Capital, with additional investment from Sanos Capital. Existing investors W Health Ventures and 2070 Health, which helped incubate the company in 2023, also participated in the round.
Co-founder and CEO Sanchit Mullick told TOI that the new funding will be used to grow go-to-market teams and commercialize their AI solutions, including BioCanvas and Prism AI. “Until now, sales have been founder-led. Our goal is to scale market education efforts and invest in making our solutions fully commercial-ready,” he explained.
Mullick, a former Infosys executive who led AI services incubation there, partnered with co-founder Dr. Salim, a pediatric vascular surgeon formerly at Boston Children’s Hospital. “Our approach stems from two decades of experience with digital systems in US healthcare, like EHRs and RCMS. There’s a treasure trove of data, but little clarity on the key business problems to address,” Mullick said.
Reveal started by focusing on problem definition for US healthcare and life sciences clients, combining clinical expertise with advanced technology. “We chose a services-first approach, focusing on understanding needs rather than pushing a product to market,” Mullick added.
The company explains that its solutions, like BioCanvas, combine structured EHR data with imaging data from CTs and MRIs to support fields such as oncology, clinical trial recruitment, and patient cohort creation. They are also piloting AI workflow automation tools like Prism AI.
Mullick noted that adoption challenges are less about data access and more about regulation and organizational culture. “There’s uncertainty around how AI healthcare regulations will evolve, and concerns among staff about job security with AI tools,” he said. To tackle this, Reveal established a design center in Providence, Rhode Island, focused on user experience and seamless integration into existing workflows.
Reveal works with a range of clients, including top pharmaceutical companies, healthcare networks, and digital health innovators. Recent projects include enhancing patient adherence for a $40 billion US medical device company.
